Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology.

[1]  L. Trojan,et al.  Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy , 2015, EJNMMI Research.

[2]  G. Xiong,et al.  Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology , 2015, ACS nano.

[3]  C. Croce,et al.  RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model , 2015, Oncotarget.

[4]  W. Mustain,et al.  Delivery of RNA nanoparticles into colorectal cancer metastases following systemic administration. , 2015, ACS nano.

[5]  M. Bellini,et al.  Protein nanocages for self-triggered nuclear delivery of DNA-targeted chemotherapeutics in Cancer Cells. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Emil F. Khisamutdinov,et al.  Enhancing immunomodulation on innate immunity by shape transition among RNA triangle, square and pentagon nanovehicles , 2014, Nucleic acids research.

[7]  Emil F. Khisamutdinov,et al.  Physicochemically Tunable Polyfunctionalized RNA Square Architecture with Fluorogenic and Ribozymatic Properties , 2014, ACS nano.

[8]  Emil F. Khisamutdinov,et al.  Addition to Entropy-Driven One-Step Formation of Phi29 pRNA 3WJ from Three RNA Fragments , 2014, Biochemistry.

[9]  Peixuan Guo,et al.  Stable RNA nanoparticles as potential new generation drugs for cancer therapy. , 2014, Advanced drug delivery reviews.

[10]  A. Ganser,et al.  Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia , 2013, Leukemia.

[11]  Burton B. Yang,et al.  Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion , 2013, Nucleic acids research.

[12]  Peixuan Guo,et al.  Ultrastable pRNA hexameric ring gearing hexameric phi29 DNA-packaging motor by revolving without rotating and coiling. , 2013, Current opinion in biotechnology.

[13]  A. Lund,et al.  MicroRNA and cancer , 2012, Molecular oncology.

[14]  X. Chen,et al.  miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells , 2012, BMC Cancer.

[15]  M. Friedrich,et al.  Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens , 2012, Molecular Cancer Therapeutics.

[16]  Peixuan Guo,et al.  Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. , 2012, Nucleic acid therapeutics.

[17]  M. Pomper,et al.  PSMA-targeted theranostic nanoplex for prostate cancer therapy. , 2012, ACS nano.

[18]  Peixuan Guo,et al.  Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. , 2012, Nano today.

[19]  Hao Yan,et al.  Challenges and opportunities for structural DNA nanotechnology. , 2011, Nature nanotechnology.

[20]  J. McNamara,et al.  Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. , 2011, Nucleic acid therapeutics.

[21]  W. Fan,et al.  Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy , 2011, International journal of nanomedicine.

[22]  Peixuan Guo,et al.  Pharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Peixuan Guo,et al.  Thermodynamically Stable RNA three-way junctions as platform for constructing multi-functional nanoparticles for delivery of therapeutics , 2011, Nature Nanotechnology.

[24]  X. Ye,et al.  Targeted Delivery of Mutant Tolerant Anti-Coxsackievirus Artificial MicroRNAs Using Folate Conjugated Bacteriophage Phi29 pRNA , 2011, PloS one.

[25]  Peixuan Guo,et al.  Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells. , 2011, Methods.

[26]  J. Stenvang,et al.  Silencing of microRNA families by seed-targeting tiny LNAs , 2011, Nature Genetics.

[27]  J. Läuter,et al.  MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4 , 2011, Oncogene.

[28]  Peixuan Guo,et al.  Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging. , 2011, ACS nano.

[29]  A. Ben Jemaa,et al.  Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies , 2010, Journal of experimental & clinical cancer research : CR.

[30]  M. Manoharan,et al.  Unexpected origins of the enhanced pairing affinity of 2′-fluoro-modified RNA , 2010, Nucleic acids research.

[31]  Peixuan Guo.  The emerging field of RNA nanotechnology. , 2010, Nature nanotechnology.

[32]  D. Lafontaine,et al.  Therapeutic applications of ribozymes and riboswitches. , 2010, Current opinion in pharmacology.

[33]  B. Liu,et al.  Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  L. Jaeger,et al.  In vitro Assembly of Cubic RNA-Based Scaffolds Designed in silico , 2010, Nature nanotechnology.

[35]  N. Seeman.  Nanomaterials based on DNA. , 2010, Annual review of biochemistry.

[36]  Huiqing Yuan,et al.  MicroRNAs and prostate cancer. , 2010, Acta biochimica et biophysica Sinica.

[37]  T. D. de Gruijl,et al.  Functional delivery of viral miRNAs via exosomes , 2010, Proceedings of the National Academy of Sciences.

[38]  E. Wentzel,et al.  miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. , 2009, Cancer research.

[39]  Anton P. McCaffrey,et al.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors , 2009, Nature Biotechnology.

[40]  P. Sun,et al.  MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. , 2009, Biochemical and biophysical research communications.

[41]  C. Klinge,et al.  Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells , 2009, Nucleic acids research.

[42]  Anindya Dutta,et al.  MicroRNAs in cancer. , 2009, Annual review of pathology.

[43]  T. Wurdinger,et al.  MicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators , 2008, Molecular and Cellular Biology.

[44]  E. Miska,et al.  MicroRNA—implications for cancer , 2007, Virchows Archiv.

[45]  K. Ghoshal,et al.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.

[46]  J. Paul Robinson,et al.  Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells , 2007, Cancer biology & therapy.

[47]  F. Szoka,et al.  Lipid-based Nanoparticles for Nucleic Acid Delivery , 2007, Pharmaceutical Research.

[48]  Dianqing Wu,et al.  Prostate-Specific Membrane Antigen Regulates Angiogenesis by Modulating Integrin Signal Transduction , 2006, Molecular and Cellular Biology.

[49]  D. Bacich,et al.  Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro , 2006, The Prostate.

[50]  Peixuan Guo,et al.  Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. , 2005, Nano letters.

[51]  Peixuan Guo,et al.  Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. , 2005, Human gene therapy.

[52]  J. Wolchok,et al.  Induction of autoantibodies to syngeneic prostate‐specific membrane antigen by xenogeneic vaccination , 2005, International journal of cancer.

[53]  Huajian Gao,et al.  Mechanics of receptor-mediated endocytosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[54]  E. Klein,et al.  Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. , 2005, Cancer research.

[55]  C. Mao,et al.  Bottom-up Assembly of RNA Arrays and Superstructures as Potential Parts in Nanotechnology. , 2004, Nano letters.

[56]  R. Breaker,et al.  Control of gene expression by a natural metabolite-responsive ribozyme , 2004, Nature.

[57]  S. Hoeprich,et al.  Bacterial virus phi29 pRNA as a hammerhead ribozyme escort to destroy hepatitis B virus , 2003, Gene Therapy.

[58]  D. S. Coffey,et al.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.

[59]  D. Bostwick,et al.  Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.

[60]  C. Zhang,et al.  Inter-RNA interaction of phage phi29 pRNA to form a hexameric complex for viral DNA transportation. , 1998, Molecular cell.

[61]  Mike Wilson,et al.  Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  P. Schellhammer,et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.

[63]  W. Fair,et al.  Expression of the prostate-specific membrane antigen. , 1994, Cancer research.

[64]  R. Reid,et al.  Identification of bacteriophage phi 29 prohead RNA domains necessary for in vitro DNA-gp3 packaging. , 1994, The Journal of biological chemistry.

[65]  Peixuan Guo,et al.  Biological and biochemical properties of the small viral RNA(pRNA) essential for the packaging of the dsDNA of phage ø29 , 1994 .

[66]  J. Szostak,et al.  Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures , 1992, Nature.

[67]  J. Rossi,et al.  Ribozymes as potential anti-HIV-1 therapeutic agents. , 1990, Science.

[68]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[69]  K. Jain.  The role of nanobiotechnology in drug discovery. , 2009, Advances in experimental medicine and biology.

[70]  J. McNamara,et al.  Cell-specific aptamers for targeted therapies. , 2009, Methods in molecular biology.

[71]  P. Guo,et al.  Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells , 2006, Gene Therapy.

[72]  N. Seeman.  DNA Nicks and Nodes and Nanotechnology , 2001 .

[73]  N. Seeman.  DNA nanotechnology: novel DNA constructions. , 1998, Annual review of biophysics and biomolecular structure.

[74]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  L. Gold.  The SELEX process: a surprising source of therapeutic and diagnostic compounds. , 1995, Harvey lectures.